• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Genetic Contributors of Incident Stroke in 10,700 African Americans With Hypertension: A Meta-Analysis From the Genetics of Hypertension Associated Treatments and Reasons for Geographic and Racial Differences in Stroke Studies
Conclusion: This study highlights biologically plausible genetic determinants for incident stroke in hypertensive AAs. Ultimately, a better understanding of genetic risk factors for stroke in AAs may give new insight into stroke burden and potential clinical tools for those among the highest at risk.
Source: Frontiers in Genetics - December 21, 2021 Category: Genetics & Stem Cells Source Type: research

Genes, Vol. 12, Pages 1537: Influence of Renal Impairment and Genetic Subtypes on Warfarin Control in Japanese Patients
Kazuyuki Nagatsuka The genotypes of vitamin K epoxide reductase complex 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) can influence therapeutic warfarin doses. Conversely, nongenetic factors, especially renal function, are associated with warfarin maintenance doses; however, the optimal algorithm for considering genes and renal dysfunction has not been established. This single-center prospective cohort study aimed to evaluate the factors affecting warfarin maintenance doses and develop pharmacogenetics-guided algorithms, including the factors of renal impairment and others. To commence, 176 outpatients who were prescrib...
Source: Genes - September 28, 2021 Category: Genetics & Stem Cells Authors: Tomotaka Tanaka Masafumi Ihara Kazuki Fukuma Haruko Yamamoto Kazuo Washida Shunsuke Kimura Akiko Kada Shigeki Miyata Toshiyuki Miyata Kazuyuki Nagatsuka Tags: Article Source Type: research

Utility of a Dedicated Pediatric Cardiac Anticoagulation Program: The Boston Children’s Hospital Experience
Abstract Congenital heart disease is the leading cause of stroke in children. Warfarin therapy can be difficult to manage safely in this population because of its narrow therapeutic index, multiple drug and dietary interactions, small patient size, high-risk cardiac indications, and lack of data to support anticoagulation recommendations. We sought to describe our institution’s effort to develop a dedicated cardiac anticoagulation service to address the special needs of this population and to review the literature. In 2009, in response to Joint Commission National Patient Safety Goals for Anticoagulation, Boston...
Source: Mammalian Genome - January 8, 2015 Category: Genetics & Stem Cells Source Type: research